Ainos (NASDAQ:AIMD) Trading Down 1.5% – Here’s Why

Ainos, Inc. (NASDAQ:AIMD) dropped 1.5% during mid-day trading on Tuesday . The company traded as low as $1.30 and last traded at $1.31. Approximately 17,485 shares traded hands during mid-day trading, a decline of 68% from the average daily volume of 55,193 shares. The stock had previously closed at $1.33.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings raised shares of Ainos from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, May 26th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Ainos currently has a consensus rating of “Sell”.

Ainos Price Performance

The company has a market cap of $11.16 million, a P/E ratio of -0.45 and a beta of 2.43. The company has a fifty day moving average price of $1.90 and a two-hundred day moving average price of $1.75. The company has a debt-to-equity ratio of 1.58, a quick ratio of 0.50 and a current ratio of 0.55.

Ainos (NASDAQ:AIMD) last released its earnings results on Wednesday, May 13th. The company reported ($0.41) earnings per share (EPS) for the quarter. Ainos had a negative net margin of 11,912.10% and a negative return on equity of 160.55%.

Insider Buying and Selling at Ainos

In other Ainos news, major shareholder Carbon Nano Technology Taiwan sold 41,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $2.36, for a total transaction of $96,760.00. Following the transaction, the insider owned 948,925 shares of the company’s stock, valued at $2,239,463. The trade was a 4.14% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Chun-Jung Tsai sold 27,718 shares of the business’s stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $1.87, for a total value of $51,832.66. Following the transaction, the director directly owned 658,199 shares in the company, valued at $1,230,832.13. This trade represents a 4.04% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders purchased 7,800 shares of company stock worth $15,946 and sold 179,788 shares worth $359,247. Corporate insiders own 9.79% of the company’s stock.

Hedge Funds Weigh In On Ainos

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Two Sigma Investments LP acquired a new position in Ainos during the third quarter worth $80,000. Renaissance Technologies LLC raised its position in Ainos by 13.1% during the fourth quarter. Renaissance Technologies LLC now owns 66,300 shares of the company’s stock worth $109,000 after acquiring an additional 7,700 shares in the last quarter. DRW Securities LLC lifted its stake in Ainos by 272.6% in the fourth quarter. DRW Securities LLC now owns 66,211 shares of the company’s stock valued at $109,000 after acquiring an additional 48,439 shares during the last quarter. Finally, Mariner LLC acquired a new stake in Ainos in the fourth quarter valued at $37,000.

Ainos Company Profile

Ainos, Inc (NASDAQ: AIMD) is a clinical?stage biopharmaceutical company dedicated to developing inhalation therapies for patients with chronic pulmonary disorders. The company’s proprietary platform centers on a dry powder inhalation technology designed to deliver therapeutic agents directly to the lungs, potentially improving drug distribution and reducing systemic side effects compared to traditional oral or intravenous formulations.

The lead product candidate, AI?401, is an inhaled formulation of ibuprofen in a dry powder format.